Last €64.17 EUR
Change Today +0.61 / 0.96%
Volume 24.1K
MRK On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
Stuttgart
As of 3:16 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa (MRK) Snapshot

Open
€63.50
Previous Close
€63.56
Day High
€64.17
Day Low
€63.46
52 Week High
01/22/14 - €67.85
52 Week Low
09/12/13 - €55.20
Market Cap
27.9B
Average Volume 10 Days
501.2K
EPS TTM
€2.91
Shares Outstanding
129.2M
EX-Date
05/12/14
P/E TM
22.1x
Dividend
€0.95
Dividend Yield
1.50%
Current Stock Chart for MERCK KGAA (MRK)

Related News

No related news articles were found.

merck kgaa (MRK) Related Businessweek News

No Related Businessweek News Found

merck kgaa (MRK) Details

Merck KGaA, together with its subsidiaries, discovers, develops, manufactures, and markets products in the pharmaceutical and chemical sectors worldwide. It operates through four divisions: Merck Serono, Consumer Health, Performance Materials, and Merck Millipore. The Merck Serono division provides prescription medicines for the treatment of cancer, multiple sclerosis, infertility, growth disorders, cardiovascular, and metabolic diseases and allergies. The Consumer Health division offers over-the-counter pharmaceuticals for mobility and agility, everyday health protection, women’s and children’s health, and cough and cold under the Bion 3, Nasivin, Femibion, Seven Seas, Sangobion, Cebion, Sedalmerck, and Kytta brand names. The Performance Materials division provides specialty chemicals for use in various end products, such as liquid crystals for displays; LED materials for lighting, and OLED materials for lighting and displays; functional materials for solar panels and energy solutions; pigments, active ingredients, and fillers for cosmetics, food, and pharmaceutical products; and pigments and functional materials for coatings, printing, and plastics. The Merck Millipore division offers tools and laboratory chemicals that are used in the research, pharmaceutical and biotechnology industries, and analytical and clinical laboratories. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

38,273 Employees
Last Reported Date: 05/15/14
Founded in 1668

merck kgaa (MRK) Top Compensated Officers

Chairman of Executive Board
Total Annual Compensation: €5.4M
General Partner, Member of Executive Board an...
Total Annual Compensation: €4.5M
General Partner, Member of Executive Board an...
Total Annual Compensation: €4.5M
General Partner and Member of Executive Board
Total Annual Compensation: €3.7M
Compensation as of Fiscal Year 2013.

merck kgaa (MRK) Key Developments

Merck KGaA Appoints Luciano Rossetti as Executive Vice President and Global Head of Research & Development, Effective from July 21, 2014

Merck KGaA's biopharmaceutical division announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014. In his most recent role Rossetti acted as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD (in the U.S. Merck & Co.). In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas.

Ventana Medical Systems, Inc. Enters into an Agreement with Merck KGaA to Develop Companion Diagnostic Test for Cancer Treatment

Ventana Medical Systems, Inc. announced it has entered into an agreement with Merck KGaA to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials. This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Merck KGaA to Invest More Than USD 19 Million in its Biotechnology Facilities in Spanish Capital

Merck KGaA has announced the investment of more than USD 19 million in its biotechnology facilities in Spain. It will invest the funds between 2014 and 2016, and this investment will represent an increase of 50% of the production capacity of the biotechnology plant.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:GR €64.11 EUR +0.55

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Koninklijke DSM NV €52.44 EUR +0.34
Mylan Inc/PA $52.06 USD +0.67
Seiko Epson Corp ¥4,235 JPY +45.00
Sumitomo Chemical Co Ltd ¥383.00 JPY +3.00
Takeda Pharmaceutical Co Ltd ¥4,666 JPY -7.00
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 21.5x
Price/Sales 2.5x
Price/Book 2.4x
Price/Cash Flow 3.9x
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA, please visit www.merck.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.